[go: up one dir, main page]

WO2021087127A8 - Cannabinoids and uses thereof - Google Patents

Cannabinoids and uses thereof Download PDF

Info

Publication number
WO2021087127A8
WO2021087127A8 PCT/US2020/057985 US2020057985W WO2021087127A8 WO 2021087127 A8 WO2021087127 A8 WO 2021087127A8 US 2020057985 W US2020057985 W US 2020057985W WO 2021087127 A8 WO2021087127 A8 WO 2021087127A8
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoid compounds
disease
pharmaceutical compositions
cannabinoids
compositions including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/057985
Other languages
French (fr)
Other versions
WO2021087127A1 (en
Inventor
Hongfeng Deng
Tama Evron
Clifton David LEIGH
César Reiriz ARMENTAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of WO2021087127A1 publication Critical patent/WO2021087127A1/en
Publication of WO2021087127A8 publication Critical patent/WO2021087127A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.g., a fibrotic disease or an inflammatory disease) in a subject in need thereof.
PCT/US2020/057985 2019-10-29 2020-10-29 Cannabinoids and uses thereof Ceased WO2021087127A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19382942.1 2019-10-29
EP19382942 2019-10-29
US201962938080P 2019-11-20 2019-11-20
US62/938,080 2019-11-20

Publications (2)

Publication Number Publication Date
WO2021087127A1 WO2021087127A1 (en) 2021-05-06
WO2021087127A8 true WO2021087127A8 (en) 2021-07-15

Family

ID=75715603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/057985 Ceased WO2021087127A1 (en) 2019-10-29 2020-10-29 Cannabinoids and uses thereof

Country Status (1)

Country Link
WO (1) WO2021087127A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058251A1 (en) * 2002-12-19 2004-07-15 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
CA2650567A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US20130338220A1 (en) * 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives

Also Published As

Publication number Publication date
WO2021087127A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2020012800A (en) Cannabinoids and uses thereof.
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MX2022000711A (en) PARP1 INHIBITORS.
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MA46990B1 (en) GLP-1 COMPOSITIONS AND ITS USES
SA521422143B1 (en) 15-PGDH inhibitor
GEP20217316B (en) Aromatic sulfonamide derivatives
EP4516355A3 (en) Stable cannabinoid formulations
MX386086B (en) Cannabis composition
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
WO2018226622A8 (en) Compounds for treating huntington's disease
MA43335B1 (en) Transthyretin (ttr) arni compositions and methods for use thereof for the treatment or prevention of diseases associated with ttr
JOP20220056A1 (en) RIP1 inhibitory compounds, modes of action and use
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
MX2009009207A (en) Methods and compositions for normalizing meibomian gland secretions.
EP4596048A3 (en) Cd73 inhibitors
EP4545589A3 (en) Compositions comprising glucose and hemicellulose and their use
WO2021062231A3 (en) Cannabinoid prodrug compounds
MX2020012281A (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof.
MX2021003643A (en) Terpinoid derivatives and uses thereof.
PH12021550304A1 (en) Novel medicament for treating inflammatory bowel disease
MX2023005913A (en) Benzenesulfonamide derivatives and uses thereof.
CR20210029A (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2017009257A3 (en) Pectin compositions for preventing and treating inflammatory diseases
EP3820477A4 (en) Compounds, compositions, and methods for the treatment of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20880939

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20880939

Country of ref document: EP

Kind code of ref document: A1